Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00557193 · OUTCOME

Percent Probability for Event-free Survival (EFS) for Patients on Arm A

Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia · Source last updated 2024-07-15

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage probability
Interval / dispersion
90% Confidence Interval
Time frame
From start of post-induction therapy for up to 10 years

What was measured

EFS time is defined as time from treatment assignment to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. EFS is constructed using the Kaplan-Meier life table method with confidence interval based on standard errors computed using the method of Peto and Peto.

Analysis population: All Eligible patients treated in Arm A (standard risk MLL-G).

Groups in this outcome

Arm A (Standard Risk MLL-G)

Eligible patients with MLL-G (germline, or non-rearranged) Asparaginase: Given IV, IM, or PO Cyclophosphamide: Given IV Cytarabine: Given IV or IT Daunorubicin Hydrochloride: Given IV Dexamethasone: Given IV or PO Etoposide: Given IV Filgrastim: Given IV or SC Laboratory Biomarker Analysis: Correlative studies Leucovorin Calcium: Given IV Mercaptopurine: Given PO Methotrexate: Given IV, IT, or PO Methylprednisolone: Given IV Pegaspargase: Given IM Pharmacological Study: Correlative studies Prednisone: Given PO Therapeutic Hydrocortisone: Given IT Vincristine Sulfate: Given IV

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Arm A (Standard Risk MLL-G)60

Reported measurements

Source class 1
Values in percentage probability · Interval/dispersion: 90% Confidence Interval
GroupValueSpreadLowerUpperComment
Arm A (Standard Risk MLL-G)86.67Not reported79.4593.89Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        79.45
        upper Limit
        93.89
        value
        86.67
denoms
  1. counts
    1. group Id
      OG000
      value
      60
    units
    Participants
description
EFS time is defined as time from treatment assignment to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. EFS is constructed using the Kaplan-Meier life table method with confidence interval based on standard errors computed using the method of Peto and Peto.
dispersion Type
90% Confidence Interval
groups
  1. description
    Eligible patients with MLL-G (germline, or non-rearranged) Asparaginase: Given IV, IM, or PO Cyclophosphamide: Given IV Cytarabine: Given IV or IT Daunorubicin Hydrochloride: Given IV Dexamethasone: Given IV or PO Etoposide: Given IV Filgrastim: Given IV or SC Laboratory Biomarker Analysis: Correlative studies Leucovorin Calcium: Given IV Mercaptopurine: Given PO Methotrexate: Given IV, IT, or PO Methylprednisolone: Given IV Pegaspargase: Given IM Pharmacological Study: Correlative studies Prednisone: Given PO Therapeutic Hydrocortisone: Given IT Vincristine Sulfate: Given IV
    id
    OG000
    title
    Arm A (Standard Risk MLL-G)
param Type
NUMBER
population Description
All Eligible patients treated in Arm A (standard risk MLL-G).
reporting Status
POSTED
time Frame
From start of post-induction therapy for up to 10 years
title
Percent Probability for Event-free Survival (EFS) for Patients on Arm A
type
SECONDARY
unit Of Measure
percentage probability

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice